A man in Oslo has achieved a rare medical double victory, entering long-term remission from both a fatal bone marrow disease and HIV. The breakthrough occurred following a stem cell transplant from his brother, who possesses a rare genetic mutation that renders cells resistant to the virus.
The patient, a 63-year-old man diagnosed with HIV in 2006, underwent the transplant to treat myelodysplastic syndrome, a type of bone marrow cancer. While the procedure was intended to save him from malignancy, it resulted in what researchers describe as a likely cure for his HIV infection—marking only the tenth such instance recorded globally.
For most people living with HIV, the virus is a lifelong companion. Even with highly effective antiretroviral therapy (ART), the virus persists in “reservoirs”—hidden pockets of cells in tissues like the gut and lymph nodes. If medication is stopped, the virus typically emerges from these hiding spots and begins replicating again.
In this case, yet, the patient has remained in remission for five years. He was able to discontinue his antiretroviral medication 24 months after the transplant, and subsequent rigorous testing has failed to identify any evidence of the virus’s return.
The Genetic ‘Lock’ That Blocked the Virus
The key to this remission lies in a specific genetic variation called the CCR5Δ32/Δ32 mutation. To enter a human immune cell, most strains of HIV must bind to a receptor protein called CCR5 on the cell’s surface. The Δ32 mutation essentially deletes this receptor, effectively removing the “door” the virus uses to gain entry.
Because the patient’s brother carried this homozygous mutation, the stem cells he donated were naturally resistant to HIV. Over time, these donor cells replaced the patient’s own immune system across his blood, bone marrow, and gut tissues—a process known as full donor chimerism.
From a clinical perspective, the gut is one of the most critical areas for this replacement. As the primary viral reservoir, the gut often harbors the persistent HIV DNA that leads to relapse. By replacing these cells with resistant ones, the transplant effectively “evicted” the virus from its primary stronghold.
Analyzing the Evidence of Remission
To confirm the remission, researchers conducted an exhaustive analysis of the patient’s system. The results indicated a profound absence of the virus:
- Cellular Analysis: A study of more than 65 million immune cells showed no virus capable of multiplying.
- Tissue Biopsies: Samples from the blood and gut taken four years after the transplant showed no integrated HIV DNA.
- Immunological Response: There were no detectable HIV-specific T-cell responses, and the patient’s HIV antibody levels showed a gradual, steady decline.
Researchers publishing the findings in Nature Microbiology noted that the absence of these specific T-cell responses supports the hypothesis that the patient has achieved sustained remission.
The ‘Double Lottery’ Constraint
Despite the success of this case, clinicians emphasize that an HIV cure stem cell transplant is not a practical or scalable treatment for the millions of people living with the virus. The requirements for such a result are statistically improbable for the general population.
The patient’s recovery was the result of two rare coincidences. First, the patient needed a sibling who was a compatible match for a bone marrow transplant, a probability of roughly 25%. Second, that sibling had to possess the CCR5Δ32/Δ32 mutation, which occurs in approximately 1% of Northern European populations.
| Factor | Estimated Probability | Impact on Outcome |
|---|---|---|
| Sibling HLA Match | 25% | Required for transplant viability |
| CCR5Δ32/Δ32 Mutation | ~1% (N. Europeans) | Required for viral resistance |
| Combined Probability | ~0.25% | Extreme rarity of “double cure” |
Because of these odds, researchers describe the patient as having “won the lottery twice”—once by surviving a potentially fatal cancer and again by being cured of HIV.
What This Means for Future HIV Research
While the transplant itself is too risky and rare to be a standard therapy, these “elite” cases provide a roadmap for scientists. By studying how the virus was eradicated in this patient, researchers can better understand how to target the hidden viral reservoirs in others.
The goal is to move away from high-risk transplants and toward therapies that can mimic this effect—such as gene editing (CRISPR) to disable the CCR5 receptor in a patient’s own cells or developing “shock and kill” strategies to flush the virus out of hiding for elimination.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
The research team continues to monitor the patient to determine if the remission is permanent. The next phase of study will involve long-term tracking of immune markers to identify the earliest possible signs of viral breakthrough, which could provide critical data for future cure attempts.
Do you have questions about the latest developments in HIV research? Share this story and join the conversation in the comments below.
